NASDAQ:PRTA Prothena (PRTA) Stock Price, News & Analysis $6.07 +0.01 (+0.17%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$6.15 +0.08 (+1.30%) As of 06/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Prothena Stock (NASDAQ:PRTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Prothena alerts:Sign Up Key Stats Today's Range$5.86▼$6.2850-Day Range$4.58▼$9.7052-Week Range$4.32▼$25.42Volume1.62 million shsAverage Volume766,748 shsMarket Capitalization$326.75 millionP/E RatioN/ADividend YieldN/APrice Target$31.50Consensus RatingHold Company OverviewProthena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Read More… Prothena Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScorePRTA MarketRank™: Prothena scored higher than 73% of companies evaluated by MarketBeat, and ranked 267th out of 931 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingProthena has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageProthena has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Prothena's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Prothena are expected to grow in the coming year, from ($4.04) to ($3.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProthena has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Prothena's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.42% of the float of Prothena has been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Prothena has recently decreased by 50.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.42% of the float of Prothena has been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Prothena has recently decreased by 50.73%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.38 News SentimentProthena has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Prothena this week, compared to 4 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of Prothena is held by insiders.Percentage Held by Institutions97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prothena's insider trading history. Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTA Stock News HeadlinesProthena (NASDAQ:PRTA) Earns Neutral Rating from Cantor FitzgeraldJune 21, 2025 | americanbankingnews.comProthena Corp (PRTA) Receives Reiterated Neutral Rating from Cantor Fitzgerald | PRTA Stock NewsJune 20, 2025 | gurufocus.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.June 25, 2025 | Porter & Company (Ad)Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 19, 2025 | finance.yahoo.comProthena Announces Corporate RestructuringJune 18, 2025 | finance.yahoo.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 17, 2025 | msn.comProthena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | uk.finance.yahoo.comProthena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | businesswire.comSee More Headlines PRTA Stock Analysis - Frequently Asked Questions How have PRTA shares performed this year? Prothena's stock was trading at $13.85 at the beginning of 2025. Since then, PRTA shares have decreased by 56.2% and is now trading at $6.07. View the best growth stocks for 2025 here. How were Prothena's earnings last quarter? Prothena Corporation plc (NASDAQ:PRTA) posted its earnings results on Thursday, May, 8th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.20. The firm's quarterly revenue was up 5500.0% on a year-over-year basis. Who are Prothena's major shareholders? Top institutional shareholders of Prothena include Wellington Management Group LLP (9.66%), Price T Rowe Associates Inc. MD (6.42%), Armistice Capital LLC (4.08%) and Palo Alto Investors LP (3.08%). Insiders that own company stock include William P Scully, Gene G Kinney, Tran Nguyen, Dennis J Selkoe, Richard T Collier, Lars Ekman, Wagner M Zago, Michael J Malecek, Karin L Walker, Hideki Garren, Carol D Karp and Brandon S Smith. View institutional ownership trends. How do I buy shares of Prothena? Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prothena investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings5/08/2025Today6/25/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRTA CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees130Year FoundedN/APrice Target and Rating Average Stock Price Target$31.50 High Stock Price Target$81.00 Low Stock Price Target$6.00 Potential Upside/Downside+418.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$122.31 million Net Margins-79.94% Pretax Margin-84.00% Return on Equity-21.61% Return on Assets-19.32% Debt Debt-to-Equity RatioN/A Current Ratio9.00 Quick Ratio9.00 Sales & Book Value Annual Sales$135.16 million Price / Sales2.42 Cash FlowN/A Price / Cash FlowN/A Book Value$9.05 per share Price / Book0.67Miscellaneous Outstanding Shares53,830,000Free Float48,875,000Market Cap$326.75 million OptionableOptionable Beta-0.08 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PRTA) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.